Vitruvias Company Profile
✉ Email this page to a colleague
What is the competitive landscape for VITRUVIAS, and what generic and branded alternatives to VITRUVIAS drugs are available?
VITRUVIAS has four approved drugs.
Drugs and US Patents for Vitruvias
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vitruvias | NIFEDIPINE | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 216019-001 | Nov 18, 2022 | DISCN | No | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Vitruvias | ENTECAVIR | entecavir | TABLET;ORAL | 212106-001 | Aug 10, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Vitruvias | ENTECAVIR | entecavir | TABLET;ORAL | 212106-002 | Aug 10, 2020 | AB | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Similar Applicant Names
Here is a list of applicants with similar names.